Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A.

Rocha AG, Franco A, Krezel AM, Rumsey JM, Alberti JM, Knight WC, Biris N, Zacharioudakis E, Janetka JW, Baloh RH, Kitsis RN, Mochly-Rosen D, Townsend RR, Gavathiotis E, Dorn GW 2nd.

Science. 2018 Apr 20;360(6386):336-341. doi: 10.1126/science.aao1785.

2.

Chromatin Regulates Genome Targeting with Cisplatin.

Zacharioudakis E, Agarwal P, Bartoli A, Abell N, Kunalingam L, Bergoglio V, Xhemalce B, Miller KM, Rodriguez R.

Angew Chem Int Ed Engl. 2017 Jun 1;56(23):6483-6487. doi: 10.1002/anie.201701144. Epub 2017 May 5.

3.

Quinolizinium as a new fluorescent lysosomotropic probe.

Zacharioudakis E, Cañeque T, Custodio R, Müller S, Cuadro AM, Vaquero JJ, Rodriguez R.

Bioorg Med Chem Lett. 2017 Jan 15;27(2):203-207. doi: 10.1016/j.bmcl.2016.11.074. Epub 2016 Nov 24.

PMID:
27919658
4.

Iron-dependent lysosomal dysfunction mediated by a natural product hybrid.

Mariani A, Mai TT, Zacharioudakis E, Hienzsch A, Bartoli A, Cañeque T, Rodriguez R.

Chem Commun (Camb). 2016 Jan 25;52(7):1358-60. doi: 10.1039/c5cc09255h.

PMID:
26645586
5.

The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.

Di Fruscia P, Zacharioudakis E, Liu C, Moniot S, Laohasinnarong S, Khongkow M, Harrison IF, Koltsida K, Reynolds CR, Schmidtkunz K, Jung M, Chapman KL, Steegborn C, Dexter DT, Sternberg MJ, Lam EW, Fuchter MJ.

ChemMedChem. 2015 Jan;10(1):69-82. doi: 10.1002/cmdc.201402431. Epub 2014 Nov 13.

PMID:
25395356

Supplemental Content

Loading ...
Support Center